Bristol Myers lung cancer drug Krazati succeeds in late-stage trial

seekingalpha06-01

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its FDA-authorized cancer therapy Krazati (adagrasib), acquired with its $4.8B Mirati (MRTX) buyout this year, reached its main goal in a late-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2440769139?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg","is_english":true,"pubTime":"2024-06-01 20:53","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2440769139","market":"sg","top_or_hot":-1,"title":"Bristol Myers lung cancer drug Krazati succeeds in late-stage trial","media":"seekingalpha","content":"<div>\n<p>Bristol Myers Squibb (NYSE:BMY) announced Saturday that its FDA-authorized cancer therapy Krazati (adagrasib), acquired with its $4.8B Mirati (MRTX) buyout this year, reached its main goal in a late-...</p>\n\n<a href=\"https://seekingalpha.com/news/4112126-bristol-myers-wins-late-stage-trial-krazati\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bristol Myers lung cancer drug Krazati succeeds in late-stage trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBristol Myers lung cancer drug Krazati succeeds in late-stage trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-01 20:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4112126-bristol-myers-wins-late-stage-trial-krazati><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bristol Myers Squibb (NYSE:BMY) announced Saturday that its FDA-authorized cancer therapy Krazati (adagrasib), acquired with its $4.8B Mirati (MRTX) buyout this year, reached its main goal in a late-...</p>\n\n<a href=\"https://seekingalpha.com/news/4112126-bristol-myers-wins-late-stage-trial-krazati\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0061475181.USD","symbol_name":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4112126-bristol-myers-wins-late-stage-trial-krazati","article_id":"2440769139","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440769139","pubTimestamp":1717246424,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Bristol Myers Squibb (NYSE:BMY) announced Saturday that its FDA-authorized cancer therapy Krazati (adagrasib), acquired with its $4.8B Mirati (MRTX) buyout this year, reached its main goal in a late-s","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4585":"ETF&股票定投概念","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BMY":"施贵宝","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4534":"瑞士信贷持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4139":"生物科技","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4007":"制药","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4559":"巴菲特持仓","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4588":"碎股","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","MRTX":"Mirati Therapeutics Inc.","LU0237698245.USD":"富达环球地产基金A","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4581":"高盛持仓","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","BK4126":"金属与玻璃容器","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4532":"文艺复兴科技持仓","LU0882574055.USD":"富达全球健康医疗A ACC","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","MYE":"Myers Industries Inc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC"},"translate_title":"百时美肺癌药物Krazati后期试验成功","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYE":1,"MRTX":1,"BMY":1},"content_text":"Bristol Myers Squibb (NYSE:BMY) announced Saturday that its FDA-authorized cancer therapy Krazati (adagrasib), acquired with its $4.8B Mirati (MRTX) buyout this year, reached its main goal in a late-stage trial for lung cancer. Citing a data presentation from its Phase 3 KRYSTAL-12 study for the first time, the company said Krazati, which belongs to a drug class called KRASG12C inhibitors, improved cancer-free survival with a statistically significant and clinically meaningful effect. Bristol Myers (BMY) noted that the measure known as progression-free survival stood at a median of 5.5 months in the Krazati arm compared to 3.8 months in the comparator, thus meeting the study’s primary endpoint. KRYSTAL-12 was designed to evaluate Krazati against standard-of-care chemotherapy as a late-line option in patients with KRASG12C-mutated non-small cell lung cancer. As for safety, 94% of patients treated with KRAZATI and 86.4% with chemotherapy witnessed treatment-related adverse events, while there were no new safety signals. The trial is ongoing to evaluate the key secondary endpoint of overall survival. In 2022, the U.S. FDA greenlighted Krazati as a late-line option for NSCLC patients with KRASG12C mutations. The decision granted under the agency’s accelerated approval pathway was based on Mirati’s Phase 2 KRYSTAL-1 study data.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440769139"}